Ex vivo and in vivo HIV-1 latency reversal by "Mukungulu," a protein kinase C-activating African medicinal plant extract.

IF 5.1 1区 生物学 Q1 MICROBIOLOGY
mBio Pub Date : 2025-05-14 Epub Date: 2025-04-23 DOI:10.1128/mbio.03816-24
Khumoekae Richard, Zhe Yuan, Hsin-Yao Tang, Aaron R Goldman, Riza Kuthu, Boingotlo Raphane, Emery T Register, Paridhima Sharma, Brian N Ross, Jessicamarie Morris, David E Williams, Carol Cheney, Guoxin Wu, Karam Mounzer, Gregory M Laird, Paul Zuck, Raymond J Andersen, Sundana Simonambango, Kerstin Andrae-Marobela, Ian Tietjen, Luis J Montaner
{"title":"<i>Ex vivo</i> and <i>in vivo</i> HIV-1 latency reversal by \"Mukungulu,\" a protein kinase C-activating African medicinal plant extract.","authors":"Khumoekae Richard, Zhe Yuan, Hsin-Yao Tang, Aaron R Goldman, Riza Kuthu, Boingotlo Raphane, Emery T Register, Paridhima Sharma, Brian N Ross, Jessicamarie Morris, David E Williams, Carol Cheney, Guoxin Wu, Karam Mounzer, Gregory M Laird, Paul Zuck, Raymond J Andersen, Sundana Simonambango, Kerstin Andrae-Marobela, Ian Tietjen, Luis J Montaner","doi":"10.1128/mbio.03816-24","DOIUrl":null,"url":null,"abstract":"<p><p>New HIV latency-reversing agents (LRAs) are needed that can reactivate and/or eliminate HIV reservoirs. \"Mukungulu,\" prepared from the plant <i>Croton megalobotrys</i> Müll Arg., is traditionally used for HIV/AIDS management in northern Botswana despite an abundance of protein kinase C-activating phorbol esters (\"namushens\"). Here, we show that Mukungulu is tolerated in mice at up to 12.5 mg/kg while robustly reversing latency in antiretroviral therapy (ART)-suppressed HIV-infected humanized mice at 5 mg/kg. In primary cells from ART-suppressed people living with HIV-1, 1 µg/mL Mukungulu reverses latency at levels similar to or superior to anti-CD3/CD28 positive control, based on HIV gag-p24 protein expression, while the magnitude of HIV reactivation in peripheral blood mononuclear cells corresponds to intact proviral burden in CD4+ T-cells. Bioassay-guided fractionation identifies five namushen phorbol esters that can reactivate HIV, but when combined, they do not match Mukungulu's activity, suggesting the presence of additional enhancing factors. Together, these results identify Mukungulu as a robust natural LRA that is already in use by humans and which may warrant inclusion in future HIV cure and ART-free remission efforts.IMPORTANCECurrent HIV therapies do not act on the latent viral reservoir, which is the major obstacle toward achieving a drug-free HIV remission and/or an HIV cure. \"Mukungulu,\" a bark preparation from <i>Croton megalobotrys</i> Müll Arg., has been documented for its traditional use for HIV/AIDS management in northern Botswana. Here, we show that Mukungulu activates viral reservoirs, a key step toward identifying and potentially eliminating these reservoirs, in both cells from people living with HIV as well as in HIV-infected humanized mice. The majority of this activity is due to the abundance of five phorbol esters (\"namushens\"). This reverse pharmacology-based approach has therefore identified a potent activator of viral reservoirs that is already traditionally used by humans, which in turn can inform and advance western HIV cure and drug-free remission efforts.</p>","PeriodicalId":18315,"journal":{"name":"mBio","volume":"16 5","pages":"e0381624"},"PeriodicalIF":5.1000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077168/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"mBio","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1128/mbio.03816-24","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

New HIV latency-reversing agents (LRAs) are needed that can reactivate and/or eliminate HIV reservoirs. "Mukungulu," prepared from the plant Croton megalobotrys Müll Arg., is traditionally used for HIV/AIDS management in northern Botswana despite an abundance of protein kinase C-activating phorbol esters ("namushens"). Here, we show that Mukungulu is tolerated in mice at up to 12.5 mg/kg while robustly reversing latency in antiretroviral therapy (ART)-suppressed HIV-infected humanized mice at 5 mg/kg. In primary cells from ART-suppressed people living with HIV-1, 1 µg/mL Mukungulu reverses latency at levels similar to or superior to anti-CD3/CD28 positive control, based on HIV gag-p24 protein expression, while the magnitude of HIV reactivation in peripheral blood mononuclear cells corresponds to intact proviral burden in CD4+ T-cells. Bioassay-guided fractionation identifies five namushen phorbol esters that can reactivate HIV, but when combined, they do not match Mukungulu's activity, suggesting the presence of additional enhancing factors. Together, these results identify Mukungulu as a robust natural LRA that is already in use by humans and which may warrant inclusion in future HIV cure and ART-free remission efforts.IMPORTANCECurrent HIV therapies do not act on the latent viral reservoir, which is the major obstacle toward achieving a drug-free HIV remission and/or an HIV cure. "Mukungulu," a bark preparation from Croton megalobotrys Müll Arg., has been documented for its traditional use for HIV/AIDS management in northern Botswana. Here, we show that Mukungulu activates viral reservoirs, a key step toward identifying and potentially eliminating these reservoirs, in both cells from people living with HIV as well as in HIV-infected humanized mice. The majority of this activity is due to the abundance of five phorbol esters ("namushens"). This reverse pharmacology-based approach has therefore identified a potent activator of viral reservoirs that is already traditionally used by humans, which in turn can inform and advance western HIV cure and drug-free remission efforts.

激活蛋白激酶c的非洲药用植物提取物“Mukungulu”在体内和体外逆转HIV-1潜伏期。
需要新的艾滋病毒潜伏逆转剂(LRAs)来重新激活和/或消除艾滋病毒储存库。“Mukungulu”是由Croton megalobotrys m ll Arg.制成的。在博茨瓦纳北部,尽管含有丰富的蛋白激酶c激活佛波酯(namushen),但传统上仍用于艾滋病毒/艾滋病管理。在这里,我们发现Mukungulu在小鼠中耐受高达12.5 mg/kg的剂量,同时在抗逆转录病毒治疗(ART)抑制的hiv感染人源小鼠中以5 mg/kg的剂量强有力地逆转潜伏期。在art抑制的HIV-1感染者的原代细胞中,基于HIV gag-p24蛋白表达,1µg/mL Mukungulu逆转潜伏期的水平与抗cd3 /CD28阳性对照相似或优于抗cd3 /CD28阳性对照,而外周血单个核细胞中HIV再激活的程度与CD4+ t细胞中完整的前病毒负荷相对应。生物测定指导的分离鉴定出五种可以重新激活HIV的纳木参酚酯,但是当它们组合在一起时,它们与Mukungulu的活性不匹配,这表明存在额外的增强因素。总之,这些结果确定Mukungulu是一种强大的天然LRA,已经在人类中使用,可能有必要将其纳入未来的艾滋病毒治愈和无art缓解工作中。当前的HIV治疗不作用于潜伏病毒库,这是实现无药物HIV缓解和/或HIV治愈的主要障碍。“木孔古鲁”是一种从巴罗豆科植物(Croton megalobotrys m ll Arg)中提取的树皮制剂。它在博茨瓦纳北部的传统用途是用于艾滋病毒/艾滋病管理。在这里,我们展示了Mukungulu激活病毒库,这是在HIV感染者和HIV感染的人源化小鼠的细胞中识别和潜在地消除这些病毒库的关键一步。这种活性主要是由于丰富的五酚酯(“namushen”)。因此,这种基于反向药理学的方法已经确定了一种传统上已经被人类使用的病毒库的有效激活剂,这反过来可以告知和推进西方艾滋病治愈和无药物缓解的努力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
mBio
mBio MICROBIOLOGY-
CiteScore
10.50
自引率
3.10%
发文量
762
审稿时长
1 months
期刊介绍: mBio® is ASM''s first broad-scope, online-only, open access journal. mBio offers streamlined review and publication of the best research in microbiology and allied fields.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信